Prolonged exposure to the candidate microbicide C31G differentially reduces cellular sensitivity to agent re-exposure.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2005-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BIOPHA.2005.07.009PMID 16154719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expanding access to HIV treatment through community-based organizations : a joint publication of Sidaction, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO)

  2005cited by this paper
• Comparative Safety Evaluation of the Candidate Vaginal Microbicide C31G

  2005cited by this paper
• A phase I comparative postcoital testing study of three concentrations of C31G.

  2004cited by this paper
• AIDS epidemic update December 2004.

  2004cited by this paper
• Mouse Model of Cervicovaginal Toxicity and Inflammation for Preclinical Evaluation of Topical Vaginal Microbicides

  2004cited by this paper
• Male tolerance study of 1% C31G.

  2004cited by this paper
• A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II.

  2004cited by this paper
• EFFECTIVENESS OF COL-1492, A NONOXYNOL-9 VAGINAL GEL, ON HIV-1 TRANSMISSION IN FEMALE SEX WORKERS: A RANDOMISED, CONTROLLED TRIAL

  2003cited by this paper
• Inhibiting sexual transmission of HIV-1 infection

  2003cited by this paper
• Human Immunodeficiency Virus Type 1 Uses Lipid Raft-Colocalized CD4 and Chemokine Receptors for Productive Entry into CD4+ T Cells

  2002cited by this paper
• Considerations and development of topical microbicides to inhibit the sexual transmission of HIV

  2002cited by this paper
• Microbicides--evaluating multiple formulations of C31G.

  2002cited by this paper
• Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

  2002cited by this paper
• The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.

  2001cited by this paper
• Glycosphingolipids Promote Entry of a Broad Range of Human Immunodeficiency Virus Type 1 Isolates into Cell Lines Expressing CD4, CXCR4, and/or CCR5

  2000cited by this paper
• In Vitro and In Vivo Evaluations of Sodium Lauryl Sulfate and Dextran Sulfate as Microbicides against Herpes Simplex and Human Immunodeficiency Viruses

  2000cited by this paper
• Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate.

  1999cited by this paper
• Human Erythrocyte Glycosphingolipids as Alternative Cofactors for Human Immunodeficiency Virus Type 1 (HIV-1) Entry: Evidence for CD4-Induced Interactions between HIV-1 gp120 and Reconstituted Membrane Microdomains of Glycosphingolipids (Gb3 and GM3)

  1999cited by this paper
• A Broad-Spectrum Microbicide with Virucidal Activity against Sexually Transmitted Viruses

  1999cited by this paper
• Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.

  1998cited by this paper
• Interaction of DPPC monolayers with soluble surfactants: electrostatic effects of membrane perturbants.

  1998cited by this paper
• Changes in composition of newly synthesized sphingolipids of HeLa cells during the cell cycle -- suppression of sphingomyelin and higher-glycosphingolipid synthesis and accumulation of ceramide and glucosylceramide in mitotic cells.

  1997cited by this paper
• The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro

  1997cited by this paper
• Stimulation of phospholipid synthesis in HeLa cells by epidermal growth factor and insulin: activation of choline kinase and glycerophosphate acyltransferase.

  1996cited by this paper
• Assessment of the anti-microbial agent C31G as a spermicide: comparison with nonoxynol-9.

  1996cited by this paper
• A Dosing Study of Nonoxynol-9 and Genital Irritation

  1993cited by this paper
• A non-antibiotic antimicrobial mixture (C31G): evaluation of the antimicrobial efficiency of C31G on vaginal cultures.

  1992cited by this paper
• The Effects of Frequent Nonoxynol‐9 Use on the Vaginal and Cervical Mucosa

  1991cited by this paper
• C31G, a new agent for oral use with potent antimicrobial and antiadherence properties

  1988cited by this paper
• Effect of C31G, an antimicrobial surfactant, on healing of incised guinea pig wounds.

  1983cited by this paper
• Glucocorticoid effects on lipid metabolism in HeLa cells: inhibition of cholesterol synthesis and increased sphingomyelin synthesis.

  1980cited by this paper
• Inactivation of Herpes Simplex Viruses by Nonionic Surfactants

  1978cited by this paper
• Virucidal effect of certain chemical contraceptives on Type 2 herpesvirus.

  1976cited by this paper
• Effect of plasma membrane lipid composition on cellular susceptibility to virus-induced cell fusion.

  1972cited by this paper

• Cyclic and Acyclic Amine Oxide Alkyl Derivatives as Potential Adjuvants in Antimicrobial Chemotherapy against Methicillin-Resistant Staphylococcus aureus with an MDR Profile

  2021cites this paper
• New frontiers in female contraception (and male condoms): 2012

  2012cites this paper
• Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety

  2012cites this paper
• The future of contraception: innovations in contraceptive agents: tomorrow's hormonal contraceptive agents and their clinical implications.

  2011cites this paper
• Cervicovaginal Safety of the Formulated, Biguanide-Based Human Immunodeficiency Virus Type 1 (HIV-1) Inhibitor NB325 in a Murine Model

  2011cites this paper
• Contraceptive Efficacy, Acceptability, and Safety of C31G and Nonoxynol-9 Spermicidal Gels: A Randomized Controlled Trial

  2010cites this paper
• Temporal analysis of protozoan lysis in a microfluidic device.

  2009cites this paper
• Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G.

  2005cites this paper